• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

More Positive Vaccine News and Second-Order Effects on the Market

Like 0

By Lachlann Tierney, Tuesday, 17 November 2020

Consequences of consequences, synthetic biology just getting started In this case. The money flowing towards these companies could be the launching pad for an entirely new field of science called synthetic biology...

In today’s Money Morning…value shift gaining momentum…an even better vaccine?…synthetic biology is just getting started…and more…

As the ASX rushes to get its exchange up and running today, there was more positive vaccine news overnight in the US.

In case you’ve been living under a rock, the ASX bungled the rollout of a new system, just like their new website.

It’s starting to look like a pattern of ineptitude — I find their new website just as lacking as their old one.

Perhaps most frustrating for investors is the fact that they may have to wait to place more bullish bets.

This at a time where market jubilance is getting close to peak levels.

Three Innovative Fintech Stocks to Watch Now. Discover more.

Value shift gaining momentum

The Dow Jones Industrial Average [DJI] tacked on 1.36%, while the NASDAQ 100 [NDX] posted a more muted .39% increase.

Given the NASDAQ accumulated much of the gains so far in this run up, the shift to value on the US market at least, may be starting to gain momentum.

If the shift is well and truly on, I expect equal weight ETFs like Invesco S&P 500® Equal Weight ETF [RSP] to garner more interest.

These are ETFs that are not weighted to market cap — instead they invest equally in all the companies on an index.

For so long, these ETFs failed to capture the concentrated gains at the top end of the market, due to sluggish macroeconomic sentiment.

But this could all be changing quickly if a vaccine rollout happens sooner rather than later.

Cue the flurry of bull activity.

An even better vaccine?

The trigger for US indices today was news that (via Reuters):

‘Moderna Inc’s experimental vaccine is 94.5% effective in preventing COVID-19 based on interim data from a late-stage trial, the company said on Monday, becoming the second U.S. drugmaker to report results that far exceed expectations.’

Moderna Inc [NASDAQ:MRNA] certainly has the right ticker symbol.

Like the Pfizer/BioNTech vaccine, it uses mRNA technology to trick the body into an immune response:

Importantly though:

‘Unlike Pfizer’s vaccine, Moderna’s shot can be stored at normal fridge temperatures, which should make it easier to distribute, a critical factor as COVID-19 cases are soaring, hitting new records in the United States and pushing some European countries back into lockdowns.

‘“We are going to have a vaccine that can stop COVID-19,” Moderna President Stephen Hoge said in a telephone interview.’

Previously, concerns about how to store the Pfizer/BioNTech vaccine at the required temperature had triggered a mad rush for special fridges and dry ice solutions.

But there’s a bigger story here.

A story that goes beyond a single disease and the related vaccines, one that could make the pandemic look like a tiny blip in the grand scheme of history.

Consequences of consequences, synthetic biology just getting started

In this case, I’m talking about the second-order effects of this pandemic.

Second-order effects are defined as:

‘Every action has a consequence, and those consequences have consequences, which are called Second-Order Effects. Think of a line of dominoes—a single push causes a chain of events to occur. Once the chain starts, it’s difficult (if not impossible) to stop or reverse the cascade of cause-and-effect.’

What started in Wuhan, lead to the advent of lockdowns, masks, and a mad rush to create a vaccine.

The next domino in the causal chain?

A large amount of money pouring into companies like Moderna Inc and BioNTech SE [NASDAQ:BNTX].

Famously, Moderna was a company without a product.

However, the money flowing towards these companies could be the launching pad for an entirely new field of science called synthetic biology.

It’s a major theme in our Exponential Stock Investor service.

In short, Ryan Dinse and I think the next few decades will be shaped by this ‘synbio’ explosion.

And for the savvy investor, this means a wealth of opportunities.

Vaccine is a smokescreen for the real opportunity

You see, BioNTech and Moderna are not just vaccine companies — if anything this is a smokescreen for what they actually do.

No, before this pandemic they were very much focused on cancer immunotherapy.

Using the body’s immune system against one of the most prevalent diseases out there.

How much is this worth?

Well, it’s a harsh reality, but the virus is not where the money is.

The cancer therapy market is projected to hit US$182.0 billion by 2023.

Now if that’s not an investment opportunity, I don’t know what is.

Renewable energy is much the same too.

While everyone is piling into solar and wind companies — the second-order effects of the green energy push may be where the most lucrative opportunities lie.

Keep your eyes peeled for more on this in the coming weeks.

Regards,

Lachlann Tierney Signature

Lachlann Tierney,
For Money Morning

PS: How to Find Promising Energy Stocks — Discover why the energy market is ripe for massive disruption and how to identify innovative energy stocks. Click here to learn more.

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Lachlann Tierney

Lachlann’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • OpenAI and Microsoft Divorce?: Why this could be good for you
    By Charlie Ormond

    While breakups are rarely pretty, this one might actually benefit investors willing to look beyond the drama.

  • Three Lithium Stocks in the Buy Zone
    By Murray Dawes

    Lithium stocks jumped this week, so Murray and Callum discuss whether this could be the beginning of the second boom in lithium stocks. They also discuss a fund manager that is recovering and looking cheap

  • Every Australian Investor Has a Stake in Mining
    By James Cooper

    With its deep pool of retirement capital, Australia is on track to become the world’s primary destination for resource markets.

Primary Sidebar

Latest Articles

  • OpenAI and Microsoft Divorce?: Why this could be good for you
  • Three Lithium Stocks in the Buy Zone
  • Every Australian Investor Has a Stake in Mining
  • The next wave of AI winners
  • Could the US People Repudiate the National Debt?

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988